[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-coronary-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-coronary-syndromes":697},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,49,83,107,130,183,211,236,260,286,315,337,365,389,416,442,472,499,525,549,575,600,625,653,680],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100644842",false,"NCT07675434","Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting","CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit","CESAR","Inclusion Criteria:\n\n\\- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.\n\nExclusion Criteria:\n\n* Patient unable to provide informed consent\n* Patient not affiliated to French social security","ALL","18 Years",{"count":20,"type":21},25000,"ESTIMATED","10 Years","OBSERVATIONAL","Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.\n\nTo address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.\n\nThe primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.",[26,27,28,29,30],"Acute Coronary Syndromes","Heart Failure","Pulmonary Embolism, Deep Vein Thrombosis","HTN-Hypertension","Arrhythmia",[32,33,34,35,36],"Cardiovascular emergencies","Multimodality Imaging","Acute care","Prospective cohort","Biomarkers","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-08-01",{"date":45,"type":21},"2041-08-01",{"name":47,"class":48},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100578595","NCT06813339","Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort","A Double Blind, Placebo-controlled Study in Healthy Participants to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of UDP-003 and Followed by an Open-label Multiple-dose Patient Cohort","CTx-001","Inclusion Criteria\n\nAll Participants:\n\n1. Participant understands study procedures and provides written informed consent for the trial.\n2. Participant is able to comply with the protocol and the assessments therein.\n\nHealthy Participants (SAD and MAD cohorts):\n\n1. Healthy adult males and females, 18 to 65 years of age (inclusive) at the time of screening.\n2. Adult males and females of body mass index (BMI) ≥ 18 and ≤ 32 kg\u002Fm² and body weight ≥ 50 and ≤ 120 kg.\n3. Social smoking of less than 10 nicotine-containing products per month is acceptable. Absence of tobacco or nicotine containing product (including smoking cessation products) use, for a minimum of 2 weeks prior to dosing is required and will be confirmed by a negative cotinine test at check-in (one retest allowed at the discretion of the investigator).\n4. Medically healthy with relevant renal parameters tests not exceeding 1.5 X the upper limits and no clinically significant screening results (e.g., laboratory profiles, medical history, vital signs, ECGs, physical examination) as deemed by the Principal Investigator; one retest is permitted at investigator discretion.\n\nParticipants with ACS (MD Patient cohort):\n\n1. Adult males and females, 40 to 79 years of age (inclusive) at the time of screening, diagnosed with acute coronary syndrome (ACS), at least 12 months post event (NSTEMI or unstable angina).\n2. Adult males and females of body mass index (BMI) ≥ 18\n3. Medically stable with no clinically significant screening results (e.g., laboratory profiles including relevant renal parameters and liver function tests, medical history, vital signs, ECGs, physical examination) as deemed by the Principal Investigator.\n4. Participants on a stable regimen and dose of ACS treatment including statins, anticoagulants, blood thinners, anti-platelets or other standard of care for 3 months prior to screening and for whom no change in this treatment is planned during the participation in the study.",true,"79 Years",{"count":59,"type":21},84,"INTERVENTIONAL",[62],"EARLY_PHASE1","The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)\u002Fpharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its potential efficacy in patients.\n\nResearchers will compare UDP-003 to a placebo in a blinded manner.\n\nThis first in human, randomised, double-blind, placebo-controlled, prospective, single-centre trial with a modular dose-finding design will be conducted in 3 parts:\n\n* Part 1: 6 cohorts of 6 healthy participants receiving Single Ascending Doses (SADs),\n* Part 2: 3 cohorts of 12 healthy participants receiving Multiple Ascending Doses (MADs) (6 doses over 16 days),\n* Part 3: 1 cohort of up to 9 evaluable participants diagnosed with acute coronary syndrome (ACS; non-ST elevation myocardial infarction \\[NSTEMI\\] or unstable angina) at least 12 months post-event receiving multiple doses (6 administrations of the 25 mg\u002Fkg dose over 6 weeks).\n\nThe planned duration of the study for each participant will be:\n\n* 4 weeks for SAD Participants (1-day treatment period, 4-week safety follow-up)\n* 6 weeks for MAD Participants (16-day treatment period,4-week safety follow-up)\n* 180 Days for MD Patients (6-week treatment period, 6-month safety follow-up) Prior to participants being randomised to panels of increasing doses, all safety data will be reviewed for completed panels.",[65,26],"Atherosclerotic Cardiovascular Disease",[67,68,69,70,71,72],"Atherosclerosis","7-ketocholesterol (7KC)","Cyclodextrin","Plaque burden reduction","Healthy Participants","Acute coronary syndrome","RECRUITING",{"date":40,"type":41},{"date":76,"type":41},"2025-02-25",{"date":78,"type":21},"2027-12-30",{"name":80,"class":81},"Cyclarity Therapeutics, Inc.","INDUSTRY",1,{"id":84,"slug":4,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":60,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":82},"100602413","NCT07123181","Oregano and Basil Leaves and Coronary Artery Disease","Effects of Increasing Polyphenol Intake by Consumption of Oregano and Basil Leaves on Plasma Inflammatory and Lipid Factors and Total Urinary Polyphenol in Patients With Unstable Angina","Inclusion Criteria:\n\n* Patients diagnosed with unstable angina\n\nExclusion Criteria:\n\n* Patients diagnosed with STEMI\n* Patients undergoing coronary artery bypass grafting\n* Liver cirrhosis and advanced chronic kidney disease (CKD 5)\n* Having known inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking glucocorticoid medications\n* Pregnancy or breastfeeding","30 Years","75 Years",{"count":92,"type":21},70,[94],"NA","The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.",[26,97],"Unstable Angina (UA)","2026-06-13",{"date":100,"type":41},"2026-06-16",{"date":102,"type":41},"2025-09-01",{"date":104,"type":21},"2026-10-22",{"name":106,"class":48},"Shahid Beheshti University of Medical Sciences",{"id":108,"slug":4,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":60,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":82},"100640911","NCT07588295","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease: the LAST-COP Study","Inclusion Criteria:\n\n* Patients with chronic coronary artery disease;\n* Patients with no-ST elevation acute coronary syndrome;\n* Patients with chronic claudication (Rutherford II-III)\n* Patients with critical limb ischemia (Rutherford IV-V).\n\nExclusion Criteria:\n\n* Severe renal dysfunction\n* Severe valve disease\n* Advanced heart failure\n* Advanced liver disease\n* Chronic inflammatory or autoimmune disease\n* Use of antinflammatory drugs\n* Acute infection\n* Recent surgical procedures",{"count":114,"type":21},60,[94],"Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between circulating monocytes and intraplaque macrophages.\n\nThis study aims to evaluate and compare the presence of macrophages and their subsequent activation within coronary and peripheral atherosclerotic lesions, and to correlate these findings with the distribution of circulating monocyte subpopulations.",[118,26,119,120],"Stable Coronary Artery Disease","Critical Limb Ischemia","Intermittent Claudication","2026-05-11",{"date":123,"type":41},"2026-05-14",{"date":125,"type":41},"2024-03-18",{"date":127,"type":21},"2026-12",{"name":129,"class":48},"Maria Cecilia Hospital",{"id":131,"slug":4,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":60,"phases":139,"briefSummary":141,"conditions":142,"keywords":148,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":82},"100638421","NCT07582835","Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.","Hunting for the Long-Term EffeCts of P2Y12 Inhibitor monotHerapy and Coagulation Monitoring After PCI: an Open-label, Randomized Study.","HI-TECH 2","Inclusion Criteria:\n\n* Age ≥18 years\n* Prior (≥3 months) ACS and\u002For PCI\n* Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course\n* Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and\u002For bleeding events (defined as BARC ≥ 2) for at least 3 months\n* Written informed consent.\n\nExclusion Criteria:\n\n* Unconscious patients\n* Unable to provide written informed consent\n* Under judicial protection, tutorship or curatorship\n* Unable to understand and follow study-related instructions or unable to comply with study protocol\n* Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel\n* Severe hepatic impairment\n* Haemoglobin level \\\u003C10 g\u002FdL or platelet count \\\u003C100 000 cells\u002FmL\n* Pregnant or breastfeeding women\n* Life expectancy less than 1 year\n* Active participation in another interventional trial\n* Need for concomitant oral anticoagulation\n* History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months\n* PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization",{"count":138,"type":21},355,[140],"PHASE3","Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed. However, the optimal drug and dose for long-term monotherapy remain uncertain, as patients may experience either insufficient platelet inhibition (leading to ischemic events) or excessive inhibition (increasing bleeding risk).\n\nThe HI-TECH 2 study aims to identify the most appropriate type and dose of P2Y12 inhibitor monotherapy to achieve a balanced level of platelet inhibition within a predefined therapeutic range. The study also seeks to better understand how blood coagulation activity evolves over time after PCI.\n\nThis is a prospective, investigator-initiated, single-center, open-label study conducted in two phases. In Phase 1, patients receive stepwise reduced doses of ticagrelor or prasugrel to determine the optimal dose that most consistently achieves the desired level of platelet inhibition. In Phase 2, patients are randomly assigned to receive clopidogrel or the optimal doses of ticagrelor or prasugrel identified in Phase 1.\n\nThe main question of the study is whether optimized ticagrelor or prasugrel regimens are more effective than standard-dose clopidogrel in achieving platelet inhibition within the target therapeutic window, as measured by validated platelet function tests. Additional objectives include evaluating the role of genetic factors in treatment response and assessing markers of coagulation activation over time.\n\nThe results of this study may help personalize long-term antiplatelet therapy after PCI, improving the balance between reducing thrombotic risk and minimizing bleeding complications.",[143,144,26,145,146,147],"Coronary Artery Disease","Percutaneous Coronary Intervention","Antiplatelet Therapy","Single Antiplatelet Therapy","Coagulation Factors",[143,146,149,150,151,152,153,154,155,156,157,26,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173],"Antiplatelet therapy","Ticagrelor","Prasugrel","Coagulation biomarkers","Clopidogrel","Multiplate","VerifyNow","CYP2C19","ABCB1 gene","Dose optimization","platelet function tests (PFT)","Percutaneous Coronary Intervention (PCI)","High platelet reactivity (HPR)","Low platelet reactivity (LPR)","Bleeding Risk","Ischemic risk","prothrombin fragment F1+2","thrombin-antithrombin (TAT) complex","fibrinopeptide A","fibrinogen","D-dimer","von Willebrand factor activity (VWF)","plasminogen activator inhibitor-1 (PAI-1)","thrombin-activatable fibrinolysis inhibitor (TAFI)","circulating extracellular vesicles","2026-05-06",{"date":176,"type":41},"2026-05-13",{"date":178,"type":21},"2026-04-20",{"date":180,"type":21},"2028-04",{"name":182,"class":48},"Cardiocentro Ticino",{"id":184,"slug":4,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":82},"100638027","NCT07579624","AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis","Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements","Inclusion Criteria:\n\n* Presence of written informed consent from the patient to participate in the study.\n* Age 18 years and older.\n* Outpatient visit and\u002For hospitalization at the research center with coronary visualization performed.\n\nNon-inclusion criteria:\n\n* Absence of sufficient data on coronary anatomy and stenosis significance.\n* Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).\n* Absence of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n* Patient's unwillingness to continue participation in the study.\n* Inability to perform full analysis of single-channel ECG digital characteristics.\n* Refusal of coronary visualization methods for any reason.",{"count":190,"type":21},400,"It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.\n\nAll study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.\n\nStress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.\n\nAll patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.",[193,194,195,26],"Ischemic Heart Disease","Coronary Artery Stenosis","Stable Angina Pectoris",[197,193,198,199,200,201,202],"coronary","Single-Channel ECG","Artificial Intelligence","AI-Enhanced Screening","Non-Invasive Diagnostics","Angina",{"date":204,"type":41},"2026-05-12",{"date":206,"type":21},"2026-05-01",{"date":208,"type":21},"2027-12-01",{"name":210,"class":48},"I.M. Sechenov First Moscow State Medical University",{"id":212,"slug":4,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":218,"targetDuration":4,"studyType":60,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":82},"100581093","NCT06845826","Point-of-Care Troponin Testing in the Emergency Department","Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department to Assess Myocardial Infarction for Timely Discharge","CERMIT","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures - At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Age \\\u003C 75 years of age\n* Presenting with chest pain or chest pain-equivalent symptom suspect of acute coronary syndrome at the University Hospitals Leuven emergency department; Symptoms must have (had) a minimum duration of 15 minutes, and the current, ongoing episode of symptoms must have started within the past 12 hours.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent\n* Age \\\u003C18 years or \\>75 years\n* Chest pain or equivalent symptom with a duration shorter than 15 minutes, or an onset of the current, ongoing episode of symptoms more than 12 hours ago\n* Clinically unstable patients or confirmed STEMI patients, requiring immediate treatment\n* Patients with recent chest trauma\n* Patients transferred from another hospital\n* Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CISP.",{"count":219,"type":21},1552,[94],"The goal of this study is to evaluate whether a POC-guided testing strategy to exclude non-ST elevation myocardial infarction (NSTEMI) in acute chest pain patients presenting at the emergency department (ED) can result in a shorter length of stay compared to the routine central laboratory testing strategy. Currently, most often two high-sensitivity troponin (hs-cTn) tests are required for exclusion of NSTEMI, and central laboratories are struggling to achieve the recommended turnaround time of 60 minutes. Novel POC hs-cTn testing technology can provide results in minutes, potentially reducing the ED length of stay. This may lead to a reduction in ED crowding, which is a growing worldwide healthcare problem, resulting in poorer patient outcomes. This study may therefore improve patient burden, ED staff workload, and lead to more efficient expenditure of healthcare resources.\n\nWe will perform a prospective, cross-sectional, interventional, single-center, open label, randomized trial.\n\nAll consecutive patients older than 18 years and younger than 75 years presenting at the UZ Leuven emergency department with chest pain or chest pain-equivalent symptoms suspected of an acute coronary syndrome (ACS) will be invited to participate in the study. After informed consent patients will be randomized into the point-of-care testing (POCT) group or the usual care group. Patients in the POCT group will undergo the novel POC test-guided strategy. In the POC strategy the first hs-cTnI test shortly after admission to the ED will be performed on the POC Atellica VTLi. The second test will be performed with the usual central laboratory hs-cTnT test. Patients in the usual care group will undergo the usual testing strategy with one or two hs-cTnT tests performed in the hospital's central laboratory.",[26],[224,225,226],"POCT","troponine testing","acute coronary syndrome","2026-03-16",{"date":229,"type":41},"2026-03-18",{"date":231,"type":41},"2025-06-30",{"date":233,"type":21},"2026-12-30",{"name":235,"class":48},"KU Leuven",{"id":237,"slug":4,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":4},"100627499","NCT07449429","A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US","Development and Multicenter Validation of a Privacy-Preserving OCR-LLM Pipeline for Four-Subtype Coronary Syndrome Classification Using Admission HPI Across Heterogeneous EHR Systems","OCR-LLM-CHD","Inclusion Criteria:Hospital encounters with admission HPI documenting sym\n\n2a4afaef-9dc1-47fc-874f-9dffaf7…\n\nevant to coronary syndrome subtyping.\n\nCases with sufficient documentation to assign one of four target subtypes (STEMI, NSTEMI, UA, CCS) by adjudication.\n\n\\-\n\nExclusion Criteria: Unclear subtype or incomplete\u002Funcertain time information preventing gold standard assignment.\n\nNon-CHD primary reason for admission after screening (for MIMIC-IV cohort).\n\n\\-",{"count":244,"type":21},10,"This study develops and validates a privacy-preserving OCR-LLM pipeline that converts admission history of present illness (HPI) records into structured coronary syndrome subtypes (STEMI, NSTEMI, unstable angina, and chronic coronary syndrome). The system first extracts text from de-identified HPI images using locally deployed OCR, then applies large language models with a fixed diagnostic prompt to generate subtype classification and evidence. Performance is evaluated in an internal validation cohort and multiple external datasets covering heterogeneous EHR templates, emergency department cases, and an English dataset from MIMIC-IV. A clinician usability study assesses changes in diagnostic accuracy and time with and without tool assistance.",[247,26,248,249],"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))","ST-segment Elevation Myocardial Infarction (STEMI)","Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)","2026-02-27",{"date":252,"type":41},"2026-03-04",{"date":254,"type":21},"2026-02-28",{"date":256,"type":21},"2026-03-08",{"name":258,"class":259},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":261,"slug":4,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":82},"100584490","NCT06890013","A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices","Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)","FLARE-ACS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)\n3. Capability of providing written informed consent\n4. Patients able to comply with the follow-up schedule of the study\n\nExclusion Criteria:\n\n1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction\n2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome\n3. Patients with congenital heart disease\n4. Age \\> 85 years\n5. Patients with end stage chronic kidney disease\n6. Patients with active malignancy or autoimmune diseases which limit their survival\n7. Patients with expected survival \\\u003C 1 year due to other reasons\n8. Suboptimal echocardiographic windows\n9. Inability to provide written consent\n10. Inability to comply with the follow-up schedule of the study\n11. Pregnancy\n12. Use of intravenous drugs","85 Years",{"count":269,"type":21},100,"A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.",[26,272,273],"Flow Mediated Dilation","Endothelial Function (FMD)",[226,275,276,277],"endothelial dysfunction","biomarker","flow mediated dilatation",{"date":279,"type":41},"2026-03-02",{"date":281,"type":41},"2024-06-01",{"date":283,"type":21},"2026-11-01",{"name":285,"class":48},"Aristotle University Of Thessaloniki",{"id":287,"slug":4,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":60,"phases":295,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100626803","NCT07440381","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) Trial","PERSUADE","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and females at birth\n* Admitted for ACS caused by an atherothrombotic coronary event;\n* Calculated LDL-c: 70-140 mg\u002FdL within 24 hours from admission for the ACS index event\n* Lipid lowering therapy on admission consisting of a low\u002Fmoderate intensity statin or a high intensity statin (HIS); or no lipid lowering therapy (naïve patients)\n* Lipid-lowering therapy at discharge (at the time of randomization) consisting of HIS or HIS + ezetimibe\n* Scheduled home discharge\n* Written informed consent provided; patients who are unable to give informed consent for any reason will be excluded from the study.\n\nExclusion Criteria:\n\n* Patients already treated with HIS+Ezetimibe on admission for the ACS event,\n* Patients currently, previously or planned to be treated with PCSK9i or inclisiran,\n* Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,\n* Known allergy, sensitivity or intolerance to bempedoic acid and\u002For study drugs' formulation ingredients (e.g. lactose intolerance),\n* Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid\n* Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),\n* Patients with plasma triglycerides concentration exceeding 400 mg\u002FdL (4.52 mmol\u002FL),\n* Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),\n* Unstable clinical status (hemodynamic or electrical instability),\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 using the CKD-EPI formula),\n* Active liver disease or hepatic dysfunction (AST or ALT levels \\> 3xUNL),\n* Current enrolment in another investigational device or drug study,\n* Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception,\n* Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.",{"count":294,"type":21},600,[140],"Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking. The investigators therefore would like to see whether early (pre-discharge) initiation of an oral triple lipid-lowering therapy including bempedoic acid, high-intensity statin (HIS), and ezetimibe is superior to usual care in reducing LDL-c levels at 8 weeks after randomization in patients hospitalized for ACS.",[26,298,299],"Secondary Prevention","Lipids",[301,302,303,304,305],"ACS","Lipid-lowering therapy","atherothrombotic coronary event","secondary prevention","triple oral lipid lowering therapy","2026-02-26",{"date":250,"type":41},{"date":309,"type":21},"2026-09",{"date":311,"type":21},"2027-08",{"name":313,"class":48},"Heart Care Foundation",35,{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":60,"phases":323,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":333,"leadSponsor":335,"locationsCount":4},"100622402","NCT07383155","Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","BRIGHT-HBR","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical evidence of NSTE-ACS or recent stabilized STEMI (≥48 hours after symptom onset) undergoing PCI\n* The patient meets the ARC criteria for HBR (≥1 major criterion or ≥2 minor criteria)\n* The patient or legal representative has been fully informed and written informed consent has been obtained\n\nExclusion Criteria:\n\n* STEMI patients within 48 hours of symptom onset\n* CABG or PCI within the prior 6 months, including for the present clinical syndrome\n* Cardiogenic shock\n* Coronary artery disease unsuitable for revascularization or requiring CABG\n* Confirmed or suspected aortic dissection\n* Treatment with a glycoprotein IIb\u002FIIIa inhibitor within 2 hours prior to the PCI (use of intravenous heparin prior to or at the time of randomization is acceptable)\n* Allergy to UFH, bivalirudin, aspirin, clopidogrel, ticagrelor, or contrast agents that cannot be adequately pre-medicated, or any prior anaphylaxis to these agents\n* Any non-cardiac conditions with an expected life expectancy of ≤12 months\n* Patients deemed by the investigator to be clinically unsuitable for coronary angiography and PCI, or who are unlikely to be able to comply with the protocol requirements, including medication adherence and follow-up visits",{"count":322,"type":21},5270,[324],"PHASE4","Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.\n\nMethods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.\n\nConclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.",[144,327,26,328],"High Bleeding Risk","Anticoagulant Therapy","2026-02-01",{"date":331,"type":41},"2026-02-03",{"date":329,"type":21},{"date":334,"type":21},"2028-12-31",{"name":336,"class":48},"Shenyang Northern Hospital",{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":60,"phases":346,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":364},"100587388","NCT06927739","Focused Orticumab Research for Treating Inflammation in Coronary Arteries","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants With Prior Myocardial Infarction Who Have Elevated Coronary Inflammation Based on FAI Score Assessed by CCTA","FORTIFY","Inclusion Criteria:\n\n1. Participant must provide informed consent before any study specific activities are performed, must be able and willing to meet all requirements for randomization and must adhere to the schedules of activities.\n2. Participant must be \\>180 days after presumed type-1 myocardial infarction (i.e., due to plaque rupture or erosion, either STEMI or NSTEMI) without subsequent unstable or severe angina (Canadian Cardiovascular Society Class 3 or 4) at the time of enrollment. Participants who have undergone PCI are allowed.\n3. Participant must be on a stable cardiovascular treatment regimen consistent with local treatment guidelines for post-AMI patients (such as maximally tolerated statin and\u002For PCSK9 inhibitor medication for LDL reduction, antiplatelet medication, and hypertension treatment).\n4. Participant must have an evaluable, pre-randomization CCTA with one of the following:\n\n   1. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 50th centile (per reference standard) for their age group in at least two coronary arteries or\n   2. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 75th centile (per reference standard) for their age group in at least one coronary artery\n5. Participant must have body mass index (BMI) ≤ 40 kg\u002Fm2.\n6. Adult male and female participants ≥18 years of age at the Screening Visit:\n\nFor female participants, the participant must not be pregnant or lactating and must be one of the following:\n\n1. Postmenopausal, defined as amenorrhea for ≥ 12 months following cessation of all exogenous hormonal treatments; follicle stimulating hormone levels may be obtained at the investigator's discretion to confirm the participant is postmenopausal.\n2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilization.\n3. Females of childbearing potential must have a negative serum or urine pregnancy test prior to the start of study drug. In the case of positive urine pregnancy testing, a negative serum sample for pregnancy testing, to confirm that the participant is not pregnant, must be obtained prior to start of study. They must also agree to use an adequate method of contraception from Baseline through the End of the study or for 30 days after the last dose of study drug (whichever is longer), which include the following: sexual abstinence (if preferred and usual lifestyle of the participant), condom with spermicidal gel, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depo progesterone injections, progesterone implant (i.e., Implanon®), NuvaRing®, Ortho Evra®.\n\nFor male participants - Nonsterile male participants with sexual partners of childbearing potential must agree to use an adequate method of contraception, including sexual abstinence (if preferred and usual lifestyle of the participant), from Baseline through the End of the study.\n\nExclusion Criteria:\n\n1. History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.\n2. Percutaneous coronary intervention or invasive diagnostic coronary angiogram planned after screening. Eligible participants who have an invasive diagnostic coronary angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.\n3. History of or planned coronary artery bypass grafting.\n4. Documented episode of post-MI pericarditis in the 3 months before enrollment.\n5. Presence of unstable or uncontrolled angina. Canadian CV society (CCS) angina class \\> 2.\n6. Ongoing New York Heart Association Class IV HF.\n7. Poorly controlled type 1 or type 2 diabetes mellitus (hemoglobin A1c \\>8.0%).\n8. Increased risk of bleeding:\n\n   1. With history or presence of any bleeding disorder.\n   2. Signs of ongoing bleeding at screening (e.g., identified macroscopic bleeding, low hemoglobin presumed to be caused by bleeding) or high risk for major bleeding in accordance with the Investigator's assessment (participants taking clinically indicated antiplatelet and antithrombotic agents are acceptable).\n   3. Known severe liver disease (e.g., \\>5´ upper limit of normal elevations in ALT and\u002For AST and other evidence of grade 3 or higher criteria applies such as from the CTCAE 5.0 guidelines).\n9. History or presence of any of the following:\n\n   1. Ongoing infection or febrile illness.\n   2. Ongoing persistent or permanent atrial fibrillation or flutter.\n   3. Cancer within 5 years before randomization, with the exception of non-melanoma skin cancer.\n   4. Alcohol or substance abuse within 6 months before randomization, as judged by the investigator.\n   5. Known history of hypersensitivity reactions to other biologics, to human IgG preparations, or to any component of orticumab, or ongoing severe allergy as judged by the investigator.\n   6. Active positive results on screening for serum hepatitis C core antibody.\n   7. Clinically documented hepatitis B or HIV.\n10. Any clinically important abnormalities in clinical chemistry, hematology, coagulation parameters, as judged by the investigator.\n11. Blood pressure values at screening (taken as the average of triplicate measurements):\n\n    1. Systolic blood pressure \\\u003C 90 mmHg or \\> 180 mmHg.\n    2. Diastolic blood pressure \\> 100 mmHg.\n    3. One triplicate retest (repeat of all 3) will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized\n    4. Participants who are excluded based on elevated blood pressure may be rescreened following adequate treatment.\n12. Participants with any of the following contraindications to CCTA.\n\n    1. eGFR \\\u003C 40 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, or end stage renal disease treated with kidney transplant or renal replacement therapy.\n    2. Allergy to iodinated contrast.\n    3. History of contrast-induced nephropathy.\n    4. Contraindication to nitroglycerin.\n    5. Rapid heart rate that is uncontrolled by medical therapy.\n    6. Inability to hold breath for at least 6 seconds.\n13. Use of any of the following in the 180 days before randomization: IL-17 inhibitor, TNF inhibitor, IL-6 inhibitor, IL-1β inhibitor, methotrexate, cyclosporine, apremilast, colchicine, systemic steroids (topical steroid use is allowed).\n14. COVID-19 vaccine within 90 days of screening CCTA.\n15. Participants with a confirmed positive COVID-19 test within 90 days of screening CCTA.\n16. Receipt of any investigational device or therapy within 6 months or 5 half-lives before screening (whichever is longer).\n17. Planned participation in an additional investigational study of an intervention or biologic before the end of the follow-up period. Participation in observational studies or studies without investigational drugs or devices is allowed.\n18. Participants who have previously been exposed to orticumab.\n19. Participants who are legally institutionalized.\n20. An employee or close relative of an employee of the sponsor, the CRO, or the study site, regardless of the employee or close relative's role.",{"count":345,"type":21},240,[347],"PHASE2","The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:\n\nClinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA\n\nResearchers will compare the effects with placebo group after 6 months of treatment\n\nParticipants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies",[26,350,351,352,353,354],"Coronary Arterial Disease (CAD)","Inflammation","Heart Disease","Myocardial Infarct","Atherosclerotic Coronary Vascular Disease","2026-01-24",{"date":357,"type":41},"2026-01-27",{"date":359,"type":41},"2025-08-11",{"date":361,"type":21},"2027-06-01",{"name":363,"class":81},"Abcentra",41,{"id":366,"slug":4,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100619724","NCT07348341","Coronary Laser Atherectomy Registry From an International Taskforce","CLARIT","Inclusion Criteria:\n\nSubjects will be included if all the following criteria are met:\n\n1. Age 18 years or over\n2. Patient willing to be included in the registry\n3. Patients with stable coronary artery disease or acute coronary syndromes with de-novo or intra-stent restenosis (ISR) coronary lesions suitable to be treated with ELCA\n\n   * Non-Crossable with ICI catheter or:\n   * Crossable with ICI catheter with significant calcium score suggesting need for calcium modification based on IVUS or OCT criteria and\u002For\n   * Non-Dilatable with 1:1 NC balloon\n4. Mandated use of ICI:\n\n   * Attempted before use of ELCA or\n   * Following ELCA and any other calcium modification strategy utilized (to evaluate whether the additional modification demonstrates significant additional modification of the calcium on ICI)\n   * Final after DES implantation or prior to use of DCB\n5. Declared PCI strategy (planned use of ELCA, need for IVL\u002Fspecialty balloons\u002Falternative atherectomy and stent strategy) prior to PCI procedure\n\nExclusion Criteria:\n\n1. Pregnant or breast feeding\n2. Unable to give informed consent\n3. PCI performed without IVCI attempt\n4. No ELCA use\n5. Allergy to clopidogrel, prasugrel or ticagrelor or non-compliance\n6. Post- cardiac arrest or haemodynamic instability\n7. Participation in another trial.",{"count":372,"type":21},500,"This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).",[118,26],[376,377,369,378,379],"excimer laser coronary atherectomy","ELCA","coronary artery disease","acute coronary syndromes","2026-01-08",{"date":382,"type":41},"2026-01-16",{"date":384,"type":21},"2026-04-30",{"date":386,"type":21},"2029-07-30",{"name":388,"class":81},"Ceric Sàrl",{"id":390,"slug":4,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100604018","NCT07144059","Impact of Non-medicalized ECG Practices Initiated by SAMU in Dispatch Strategies","Participants Are Not Assigned to Interventions Based on a Protocol","ECG-PHNM","Inclusion Criteria:\n\n* Adult patient\n* Patient regulated by the SAMU 91 between 09\u002F2023 and 12\u002F2024\n* Patient referred for coronary angiography for ST+ ACS\n* Patient registered in the E-Must register (Registry for the Evaluation in Emergency Medicine of Therapeutic Strategies for Myocardial Infarction of less than 24 hours treated by the SAMU\u002FSMUR of Île-de-France)\n\nExclusion Criteria:\n\n* Secondary transport",{"count":397,"type":21},350,"The performance of an ECG by non-medicalized prehospital teams (firefighters, first responders, paramedic ambulances) is developing across the territory to cope with the increasing demand (SAMU calls) for a service that cannot meet it (limited Mobile Emergency and Resuscitation Unit - SMUR - teams).\n\nEarly diagnosis of acute coronary syndrome is key to appropriate management. A delay in care can quickly lead to complications ranging from rhythm disorders to cardiac arrest. Furthermore, as with reperfusion in strokes, the earlier reperfusion treatment is initiated, the greater the beneficial effect in ST-segment elevation myocardial infarction (STEMI).\n\nMoreover, the main elements for diagnosing STEMI in the prehospital setting remain the ECG, along with the anamnesis (medical history) and clinical examination (typical pain).\n\nThis is an observational, retrospective and single-center study (SAMU 91) carried out between September 1, 2023 and December 31, 2024. The inclusion criteria for our study were adult patients who had been regulated by SAMU 91 during a primary intervention and who had ST+ ACS registered in the eMUST registry. The main objective was to study the difference in the admission times of patients admitted to the emergency intensive care unit of cardiology or coronary angiography and presenting with ST+ ACS on the ECG performed by a primary SMUR team versus a non-medical team referred by the SAMU. The secondary objectives were to study the descriptive variables between the two groups (SMUR and non-medicalized vector), the typicity of pain, the mortality rate and the morbidity rate between the two groups.",[26],[72,401,402,403,404,405,406,407],"infarct","STEMI","Electrocardiogram (ECG)","Coronary angiography","SAMU","SMUR","Non-medical vectors","2025-12-08",{"date":410,"type":41},"2025-12-16",{"date":329,"type":21},{"date":413,"type":21},"2026-12-31",{"name":415,"class":48},"Centre Hospitalier Sud Francilien",{"id":417,"slug":4,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":301,"eligibilityCriteria":421,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":60,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":441},"100613612","NCT07268859","Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea","Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.","Inclusion Criteria:\n\n* Between the ages of 18 and 65,\n* No severe hearing and vision problems,\n* Can speak and understand Turkish,\n* Easy to communicate with,\n* First-time sufferer of acute coronary syndrome (ACS) for the first time,\n* Decided to start ticagrelor therapy,\n* Able to adapt to treatment,\n* Individuals who volunteered to participate in the research.\n\nExclusion Criteria:\n\n* Having any problem that prevents you from communicating cognitively, emotionally and verbally,\n* Obstructive sleep abnormalities,\n* Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),\n* With metabolic abnormalities,\n* Intubated after the procedure,\n* Previously treated with ticagrelor,\n* Individuals who did not volunteer to participate in the study. Losses to follow up\n* Individuals who wish to leave the study voluntarily.\n* Saturation value below 95%,\n* The one with the arrest,\n* Who will not be able to fulfill the requirements of the work,\n* Individuals with life-threatening conditions","65 Years",{"count":424,"type":21},110,[94],"This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.",[26,150,428],"Dyspnea",[430,150,431,428,432],"Nursing","Hand fan therapy","Non-pharmacological intervention","2025-12-04",{"date":408,"type":41},{"date":436,"type":41},"2025-03-15",{"date":438,"type":21},"2026-01-30",{"name":440,"class":48},"Acibadem University",2,{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":60,"phases":451,"briefSummary":452,"conditions":453,"keywords":457,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":471},"100599991","NCT07091682","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions","BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable MAGnesium Scaffold (Freesolve) in the Treatment of Subjects With Long de Novo Lesions in Native Coronary Arteries: BIOMAG-LL","BIOMAG-LL","Inclusion Criteria:\n\nClinical Inclusion Criteria\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor, cangrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to enrollment)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.7-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion must be \\>28 mm and ≤ 38 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, and should be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure.\n\n   Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C72 hours prior to the index procedure (time window is defined as the time from the end of previous intervention to the start of index procedure)\n4. Subject is on dialysis or with impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 72 hours prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained.\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure .\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT.\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion.\n2. Left main coronary artery disease\n3. Target lesion was totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation.\n8. Target lesion is located in or supplied by an arterial or venous bypass graft.\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10.\n10. The target lesion requires treatment with the device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and \u002F or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)","80 Years",{"count":269,"type":21},[94],"The study objective is the assessment of safety and clinical performance of Freesolve 35- and 40-mm in de novo coronary artery lesions up to 38 mm length.",[143,454,455,193,26,456],"Atherosclerosis of Coronary Artery","Myocardial Ischemia","Angina Pectoris",[458,459,460,461],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","2025-11-20",{"date":464,"type":41},"2025-11-21",{"date":466,"type":41},"2025-02-18",{"date":468,"type":21},"2031-06",{"name":470,"class":81},"Biotronik AG",8,{"id":473,"slug":4,"hasResults":11,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":479,"targetDuration":4,"studyType":60,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":498},"100612346","NCT07252388","EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention","Educational Intervention for Patient's Awareness on eaRly LDL-C Lowering Using Novel Pharmacological Strategies in secondarY Prevention (EARLY)","EARLY","Inclusion Criteria:\n\n1. Age ≥18 and \\\u003C80 years old.\n2. Males and females at birth.\n3. Baseline LDL-Cholesterol:\n\n   * ≥ 130 mg\u002Fdl (in statin-naïve patients or who have not followed a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment) or\n   * ≥110 mg\u002Fdl (in patients who have received stable moderate-intensity or low-intensity statin treatment in the 4 weeks prior to enrollment) or\n   * ≥100 mg\u002Fdl (in patients who have received stable treatment with high-intensity statins in the 4 weeks prior to enrollment)\n4. Discharged at home\n5. Ability to understand the requirements of the study and to provide informed consent\n\nExclusion Criteria:\n\n1. Patients who have previously received or currently treated with PCSK9i (evolocumab or alirocumab) or siRNA (inclisiran)\n2. Unstable clinical status (hemodynamic or electrical instability)\n3. Uncontrolled cardiac arrhythmias, defined as recurrent, symptomatic ventricular tachycardia or atrial fibrillation or flutter with rapid ventricular response\n4. Severe renal dysfunction, defined by eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n5. Active liver disease or liver dysfunction, reported in the medical record or defined by AST or ALT levels \\> 3 times the upper limit of normal.\n6. Reported intolerance to statins defined by the following criteria: inability to tolerate at least two different statins; intolerance associated with confirmed and intolerable statin-related adverse effects or significant biomarker abnormalities; improvement\u002Fresolution of symptoms or biomarkers following dose decrease or discontinuation; symptoms or changes in biomarkers not attributable to established predispositions.\n7. Treatment with systemic steroids or systemic cyclosporine within the past 3 months (e.g., intravenously, intramuscularly, or orally)\n8. Known active infection or severe hematologic, metabolic, or endocrine dysfunction as judged by the Investigator.\n9. Current inclusion in other pharmacological and non-pharmacological experimental studies.\n10. Pregnancy. For women of childbearing potential (age \\\u003C 50 years and last menses \\\u003C12 months prior to screening) who have not undergone tubal ligation, oophorectomy, or hysterectomy, pregnancy will be excluded from a pregnancy test prior to inclusion in the study.\n11. Active neoplasia or very severe disease compromising short-medium term life expectancy.\n\nOnly for sites randomized to the interventional group:\n\n• Patients without a device suitable for App use (eg. Smartphone or tablet) or patients that do not consent to receive push notifications by the App.",{"count":345,"type":21},[94],"Cluster Randomized Trial to test the effectiveness of a patient level delivered educational intervention to improve the awareness on the relevance of obtaining LDL cholesterol recommended goals in patients admitted for an acute coronary syndrome, as compared to usual care. Overall, 24 sites (Coronary Care Units) will be included in the study, 12 randomized to the intervention and 12 to usual care. Overall, 240 patients will be enrolled during an acute coronary syndrome hospitalization.",[26,483],"Chronic Coronary Syndromes",[485,486,487,488,489],"educational intervention","Patient awareness","LDL cholesterol","Lipid lowering drugs","Acute Coronary Syndrome","2025-11-19",{"date":492,"type":41},"2025-11-26",{"date":494,"type":21},"2025-12-11",{"date":496,"type":21},"2027-08-11",{"name":313,"class":48},30,{"id":500,"slug":4,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":60,"phases":507,"briefSummary":508,"conditions":509,"keywords":511,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":524},"100606660","NCT07178444","Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels","EDUSCA","Inclusion Criteria:\n\n* Adult patients hospitalized for ACS (ST+ or ST-), affiliated with a social security scheme, able to understand the protocol and having signed the study consent.\n\nExclusion Criteria:\n\n* Patients with a complication of the ACS (mechanical complication, cardiogenic shock, very severe left ventricular dysfunction, presence of an intraventricular thrombus, complex ventricular rhythm disorder) ;\n* Proven cognitive impairment or decompensated psychological\u002Fpsychiatric disorder ;\n* Any progressive inflammatory and\u002For infectious condition ;\n* Any orthopedic problem precluding the physical activity ;\n* Current participation in any clinical research project aimed at reducing LDL cholesterol levels ;\n* Pregnant or breastfeeding woman ;\n* Patient receiving state medical assistance ;\n* Patient under guardianship or curatorship, or any other legal protection measure ;",{"count":506,"type":21},230,[94],"According to the World Health Organization (WHO), cardiovascular diseases are the worldwide leading cause of death. For the French public health, cardiovascular diseases are the leading cause of death for the women and the second for men. Each year in France, approximately 120,000 acute coronary syndromes (ACS) occur, including 60,000 myocardial infarctions and more than 15,000 deaths. To prevent or reverse this process, the WHO recommends early detection of the diseases and reduce behavioral and cardiovascular risk factors.\n\nFor the patient, the European Society of Cardiology (ESC) recommends the implementation of secondary prevention measures, the lifestyle modifications and the encouragement to become an actor in the management of his health. The first year, the medical follow-up is recommended at 3, 6 and 12 months.\n\nSince 2019, in order to reduce the impact of LDL cholesterol, the ESC has recommended that LDL cholesterol levels be lower than 0.55 g\u002FL accompanied by a reduction of at least 50% from their initial value. In 2023, it clarified this recommendation by recommending a laboratory reassessment within 4-6 weeks after hospital discharge.\n\nThe application of these recommendations comes up against the difficulties of real life:\n\n1. The increase in the number of elderly people and people with one or more chronic diseases;\n2. In France, the significant regional disparities in the number of physicians;\n3. In 2022, six months after hospitalization for an ACS, only 21.6% of French patients had benefited from a cardiac rehabilitation program;\n4. Within 12 months of acute coronary syndrome, only 20% to 40% of patients achieved the LDL cholesterol targets recommended by the ESC.\n\nGiven the difficulties in implementing the recommendations, investigators believe it is essential to rethink the care pathway for post-ACS patients.\n\nThe investigator's hypothesis is that, in addition to the standard pathway, a care offering access to other healthcare professionals (advanced practice nurse, dietitian, pharmacist) should increase the proportion of patients achieving LDL cholesterol targets (LDL cholesterol \\\u003C 0.55 g\u002FL and a 50% reduction in this level compared to the baseline value) at 12 months. LDL cholesterol was selected as the endpoint because it has been proven that a reduction in LDL cholesterol corresponds to a 22% reduction in cardiovascular events.\n\nTo test this hypothesis, the investigators designed a multicenter controlled and randomized trial with two parallel arms:\n\n* \"Routine Cares\" arm: Each center will program cares as usual and will schedule patient follow-up according to their wishes (cardiac rehabilitation, visits to the general practitioner and\u002For cardiologist).\n* \"Intervention\" arm: In addition to routine care as described above, the patient will receive an interdisciplinary consultation one month after hospital discharge and three consultations with the IPA (3, 6, and 12 months).\n\nIn order for the conclusions of this protocol to reflect French practices, it is planned to include 230 people who have presented with acute coronary syndrome in four healthcare facilities in France (both in Paris and outside Paris).",[510,26],"Acute Coronary Syndromes (ACS)",[226,512,513,514,515],"dyslipidemias","patient education","multidisciplinary care team","nurse practitioners","2025-10-02",{"date":518,"type":41},"2025-10-03",{"date":520,"type":21},"2025-11",{"date":522,"type":21},"2028-11",{"name":47,"class":48},4,{"id":526,"slug":4,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":531,"targetDuration":4,"studyType":60,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":441},"100564153","NCT06625463","Development and Implementation Model of Home Based Cardiac Rehabilitation With Family Empowerment Approach in Patient With ACS (HBCR in ACS)","HBCR in ACS","Inclusion Criteria:\n\n1. Patients with acute coronary syndrome who have undergone hospitalization, with a minimum home care time of 3 months and a maximum of 1 year, calculated from the day of discharge from the hospital until the time of interview.\n2. Aged 18-65 years, participants were selected with age variations representing young adults, adults and the elderly.\n3. Patients with first experience of SCA, participants were selected whether they had undergone PCI or not.\n4. Patients living with family and family involved in the patient care process.\n5. Physical condition allows for interviews. physical condition is evidenced by examination of stable vital signs (diastolic BP\n\n   \\>90, systolic \\<150 mmhg; N: 60-100x\u002Fmin; S: 36-380c, no pain). Psychological condition does not show symptoms of depression as measured by the Patient Health Questionnaire-9 instrument.\n6. Willing to participate in the study.\n\nExclusion Criteria:\n\n* Patients with comorbidities that require routine medication such as Diabetes Mellitus, hypertension, renal failure",{"count":532,"type":21},90,[94],"The aim of this clinical trial is to determine whether home-based cardiac rehabilitation with a family empowerment approach can help acute coronary syndrome patients recover. The main questions to be answered are:\n\n\\- Does home-based cardiac rehabilitation with a family approach effective in patients with acute coronary syndrome to improve health-related quality of life and peak Vo2? Researchers will compare with usual care to see if home-based cardiac rehabilitation with a family approach is more effective for improving health-related quality of life and peak Vo2 in ACS patients.\n\nPatient inclusion criteria\n\n1. Patients with acute coronary syndrome who had undergone hospitalization, with a minimum home care time of 3 months and a maximum of 1 year, calculated from the day of discharge from the hospital until the time of the interview.\n2. Aged 18-65 years old, participants were selected with age variations representing young adults, adults and the elderly.\n3. Patients with first experience of SCA, participants were selected whether they had undergone PCI or not.\n4. Patients living with family and family involved in the patient care process.\n5. Physical condition allows for interviews. physical condition is evidenced by examination of stable vital signs (diastolic BP\n\n   \\>90, systolic \\<150 mmhg; N: 60-100x\u002Fmin; S: 36-380c, no pain). Psychological condition does not show symptoms of depression as measured by the Patient Health Questionnaire-9 instrument.\n6. Willing to participate in the study.\n\nParticipants will:\n\nFor 12 weeks\n\n1. Perform walking exercises as prescribed\n2. Implement diets and stress management according to the module\n3. Quit smoking\n4. Medication compliance\n5. visit the clinic to see a cardiologist, undergo a 6-minute walk test",[536,26],"Home Based Rehabilitation",[538,539,379],"home based cardiac rehabilitation","FCEM","2025-06-11",{"date":542,"type":41},"2025-06-15",{"date":544,"type":41},"2025-01-01",{"date":546,"type":21},"2025-09-30",{"name":548,"class":48},"Gadjah Mada University",{"id":550,"slug":4,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":557,"conditions":558,"keywords":564,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":82},"100589414","NCT06954103","Mechanisms And Prognosis of Stroke-Heart Syndrome","MAP-SHS","Inclusion Criteria:\n\n1. Patients admitted within 48 hours of onset, confirmed by CT\u002FMRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).\n2. Moderate-to-severe stroke with NIHSS ≥ 5.\n\nExclusion Criteria:\n\n1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).\n2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).\n3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).\n4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).\n5. Concomitant systemic diseases such as renal failure (eGFR \\\u003C 30), autoimmune disorders, severe infections, etc.\n6. History of dementia, depression, or other psychiatric disorders.\n7. Poor compliance and inability to cooperate with follow-up.",{"count":556,"type":21},658,"The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.",[559,560,27,26,30,561,562,563],"Stroke","Myocardial Injury","Sudden Cardiac Death","Takotsubo Syndrome","Heart Rate Variability",[565],"Stroke-heart syndrome","2025-04-23",{"date":568,"type":41},"2025-05-01",{"date":570,"type":41},"2025-03-01",{"date":572,"type":21},"2028-04-01",{"name":574,"class":48},"Chensheng Pan",{"id":576,"slug":4,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":584,"studyType":23,"phases":4,"briefSummary":585,"conditions":586,"keywords":587,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":82},"100572860","NCT06738758","Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients","ELITE-ACS","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. This hospitalization for ACS, which includes ST-segment elevation MI (STEMI), non-ST-segment elevation MI (NSTEMI), or unstable angina pectoris (UA) with a GRACE score of intermediate to high risk.\n3. Written informed consent must be obtained from eligible patients prior to study enrollment.\n4. LDL-C ≥1.8 mmol\u002FL in patients using statin; LDL-C ≥2.6 mmol\u002FL in those not taking statin in the last 4 weeks.\n\nExclusion Criteria:\n\n1. Received PCSK9 inhibitor therapy within 3 months.\n2. Patient has any life-threatening severe disease, including severe liver injury and persistent elevation of serum transaminases, and severe renal failure.\n3. Patient has a history of renal or cardiac transplantation.\n4. The patient is a pregnant or breastfeeding woman or a woman planning to become pregnant.\n\nPatients judged by the investigator to be unsuitable for enrollment.",{"count":583,"type":21},6000,"1 Year","The purpose of this clinical trial is to evaluate the impact of early initiation of PCSK9 inhibitor therapy for intensive lipid-lowering in Chinese patients with acute coronary syndrome (ACS) during hospitalization on the rate of lipid goal attainment, the time to achieve guideline-recommended lipid levels within one year, and the incidence of adverse cardiovascular events.\n\nThe primary research question is whether early initiation of PCSK9 inhibitor therapy during hospitalization for ACS patients in a real-world Chinese setting can increase the rate of lipid goal attainment, shorten the time to reach guideline-recommended lipid levels within one year, and improve the risk of adverse cardiovascular events.\n\nResearchers will compare three lipid-lowering strategies: PCSK9 inhibitor therapy (with or without statins ± Ezetimibe\u002FHybutimibe), statin plus Ezetimibe\u002FHybutimibe therapy, and statin monotherapy, to assess the potential of PCSK9 inhibitor drugs in accelerating lipid goal achievement and reducing adverse cardiovascular events in ACS patients.\n\nParticipants will:\n\nReceive PCSK9 inhibitor therapy (with or without daily statins ± Ezetimibe\u002FHybutimibe) every two weeks, or daily statin plus Ezetimibe\u002FHybutimibe therapy, or daily statin monotherapy.\n\nUndergo follow-up assessments of relevant laboratory indicators at baseline, 3 days after admission, discharge, and 1, 3, 6, and 12 months post-discharge.\n\nRecord the occurrence of major adverse cardiovascular events.",[26],[26,588,589,590],"PCSK9 Inhibitor","Lipid compliance time and rate","First cardiovascular event","2025-03-13",{"date":593,"type":41},"2025-03-17",{"date":595,"type":41},"2024-12-16",{"date":597,"type":21},"2027-12-31",{"name":599,"class":48},"Yun Dai Chen",{"id":601,"slug":4,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":605,"targetDuration":4,"studyType":60,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":82},"100574898","NCT06765265","Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\nAcute Coronary Syndrome\n\n25 OH-Vitamin D levels between 30-70ng\u002Fml\n\nExclusion Criteria:\n\nHypercalcemia\n\nhypocalcemia\n\npregnancy\n\nlactation\n\nhypersensitivity to statins\n\nhypothyroidism\n\nDeranged LFTs \\& RFTs\n\nUse of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)",{"count":606,"type":21},152,[324],"there will be 2 groups of patients with acute coronary syndrome. The patients will receive one of the 2 study drugs and impact on raising Vitamin D level will be seen after 6 months",[26],[611,612,613,614,615],"atorvastatin","rosuvastatin","Vitamin D","Triglyceride","Lipid Profile","2025-03-07",{"date":618,"type":41},"2025-03-11",{"date":620,"type":41},"2025-01-05",{"date":622,"type":21},"2026-01-01",{"name":624,"class":48},"King Edward Medical University",{"id":626,"slug":4,"hasResults":11,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":60,"phases":634,"briefSummary":635,"conditions":636,"keywords":639,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":82},"100579239","NCT06821711","Optimal LDL-C Target in High-risk Patients After PCI","Targeting LDL-C to Less Than 0.8 mmol\u002FL in Patients After PCI With High Risk of Cardiovascular Disease: an Open-label, Assessor-blinded, Randomized Trial (REC-SAFETARGET Trial)","REC-SAFETARGET","Inclusion Criteria:\n\n1. Patients underwent percutaneous coronary intervention due to acute or chronic coronary syndrome\n2. Patients with ASCVD at extremely high risk\n3. Patients who are able to complete the follow-up and compliant with the allocated treatment\n\n   * ASCVD at extremely high risk is defined as fulfilling at least TWO of the following criteria:\n\n     1. PCI for acute myocardial infarction (AMI, including STEMI or NSTEMI)\n     2. Previous AMI, previous stroke, or previous intervention or surgery for peripheral vascular disease\n     3. Experienced cardiovascular event(s) with LDL-C≤1.8mmol\u002FL\n     4. LDL-C≥4.9mmol\u002FL\n     5. Diabetes\n     6. CKD (eGFR \\\u003C 60 ml\u002Fmin\u002F1.73m2)\n     7. Current smoking\n     8. Recurrent cardio\u002Fcerebrovascular events\n     9. History of premature ASCVD (\\\u003C 55 male, \\\u003C 65 female)\n     10. Complex PCI (fulfilling at least one of the following criteria: multivessel disease; in-stent restenosis; ≥ 3 stents implanted; total stent length ≥ 60 mm; bifurcation; left main disease; target lesions allocated in bypass graft; chronic total occlusion (≥ 3 months of occlusion))\n\nExclusion Criteria:\n\n1. Age less than 18 years;\n2. Unable to give informed consent or currently participating in other trials;\n3. Patient who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to randomization in women of child-bearing potential according to local practice), or plans to become pregnant during treatment;\n4. Concurrent medical condition with a life expectancy of less than 3 years;\n5. Hemodynamic unstable;\n6. Active liver disease or hepatic dysfunction (persistent unexplained ALT\u002FAST elevations (≥ 3 × ULN)), patients with a transient increase ALT\u002FAST due to the acute MI may be enrolled;\n7. Unable to reach the LDL-C target by known intolerance or contradiction of lipid control medications;\n8. LDL-C ≤ 1.4 mmol\u002FL at baseline without any lipid control medication lowering LDL-C;\n9. Known active infection or critical hematologic\u002Fendocrine dysfunction.",{"count":633,"type":21},12000,[94],"Extensive evidence from epidemiological, genetic, and randomized controlled trials (RCTs) of lipid-lowering therapies has firmly established a causal relationship between low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD), establishing LDL-C as both a pathogenic risk factor and a critical therapeutic target.\n\nLipid-lowering therapies targeting LDL-C have significantly decreased the overall risk in ASCVD patients. Consequently, current guidelines recommend, based on risk stratification, lowering LDL-C levels in high-risk ASCVD patients to \\\u003C1.4 mmol\u002FL with a ≥50% reduction from baseline. Findings from PROVE IT-TIMI 22, IMPROVE-IT, ODYSSEY OUTCOMES, and FOURIER-OLE trials suggest that achieving extremely low LDL-C levels may further reduce the risk of cardiovascular events in ASCVD patients without substantially increasing clinically relevant adverse events; however, randomized data was still scarce in supporting this notion.\n\nAgainst these backgrounds, we have designed this trial to investigate whether targeting LDL-C levels \\\u003C0.8 mmol\u002FL in high-risk ASCVD patients results in a significant reduction in adverse events compared to targeting LDL-C levels of 0.8-1.4 mmol\u002FL.",[637,26,144,638],"Chronic Coronary Syndrome","High Risk Patient",[72,640,641,642,643],"Chronic coronary syndrome","Percutaneous coronary intervention","LDL-C","lipid","2025-02-17",{"date":646,"type":41},"2025-02-19",{"date":648,"type":21},"2025-02-20",{"date":650,"type":21},"2029-08-15",{"name":652,"class":48},"Xijing Hospital",{"id":654,"slug":4,"hasResults":11,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":660,"enrollmentInfo":661,"targetDuration":584,"studyType":23,"phases":4,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":679},"100574000","NCT06753591","PRemature Acute Myocardial Infarction Register of Serbia","Clinical Characteristics and Outcomes of Patients with Premature Acute Myocardial Infarction in Serbia - a Multicenter National Study","PRAMIRS","Inclusion Criteria:\n\nPatients aged ≤ 45 years. Clinical and laboratory diagnosis of acute myocardial infarction (AMI) based on the Universal Definition of Myocardial Infarction.\n\nVoluntary participation with signed informed consent.\n\nExclusion Criteria:\n\nPatients aged \\> 45 years.","45 Years",{"count":662,"type":21},1000,"This observational multicentric national study aims to understand better acute myocardial infarction (heart attack) in young adults aged 45 years or younger in Serbia. By analyzing patient characteristics, medical history, test results, and treatment outcomes, the research seeks to identify factors contributing to heart attacks in this population and improve prevention and treatment strategies.\n\nParticipants will undergo routine tests during hospitalization, and specific blood samples will be collected for advanced analyses, including genetic testing. Follow-up will include periodic check-ins to monitor health outcomes.\n\nThe study will also explore differences in heart attack causes and outcomes in younger individuals compared to older populations, focusing on risk factors like smoking, cholesterol levels, and genetic predisposition.\n\nParticipation is voluntary, and all collected data will remain confidential.",[26],[666,667,668,669],"Acute Myocardial Infarction","Premature","Young Adults","National Registry","2024-12-30",{"date":672,"type":41},"2024-12-31",{"date":674,"type":41},"2024-09-25",{"date":676,"type":21},"2026-09-25",{"name":678,"class":48},"Cardiology Society of Serbia",11,{"id":681,"slug":4,"hasResults":11,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":686,"conditions":687,"keywords":688,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":692,"completionDateStruct":693,"leadSponsor":695,"locationsCount":4},"100572526","NCT06734416","Evaluation of the Role of Brain Natriuretic Peptide in Acute Coronary Syndrome .","Inclusion Criteria:\n\n* patients with acute coronary syndrome.\n\nExclusion Criteria:\n\n* Patients with previous MI\n* Eection fraction (EF) less than 30%\n* Patients having cardiomyopathy\n* Patients having renal, liver, malignant, infectious, or inflammatory diseases .",{"count":269,"type":21},"The measurements of the natriuretic peptide are useful and beneficial for risk stratification irrespective of the cause during admission time or during hospital stay course. the aim of the study is to Assessment of the role of Brain natriuretic peptide in diagnosis of acute coronary syndrome . Evaluation of the relation of Brain natriuretic peptide to the severity and occurrence of complications in acute coronary syndrome .",[26],[689],"Brain natriuretic peptide","2024-12-11",{"date":595,"type":41},{"date":544,"type":21},{"date":694,"type":21},"2026-03-01",{"name":696,"class":48},"Assiut University",""]